GKOS trades 19.3% below Wall Street's consensus target of $190.75.
Last 12 months price action with 12-month analyst target path
The base valuation assumes GKOS achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 25 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 24, 2026, Glaukos Corporation (GKOS) has a Wall Street consensus price target of $190.75, based on estimates from 25 covering analysts. With the stock currently trading at $159.86, this represents a potential upside of +19.3%. The company has a market capitalization of $9.43B.
Analyst price targets range from a low of $150.00 to a high of $215.00, representing a 34% spread in expectations. The median target of $195.00 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 18 analysts rating the stock as a Buy or Strong Buy,6 rating it Hold, and 1 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, GKOS trades at a trailing P/E of -48.7x. Analysts expect EPS to grow +90.5% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 ATRCAtriCure, Inc. | $3.0B | $58.83 | $57.29 | -2.6% | Buy | 550.3x | 19 |
 NVCRNovocure Ltd | $1.9B | $16.67 | $26.00 | +56.0% | Buy | — | 15 |
 TNDMTandem Diabetes Care, Inc. | $1.2B | $17.50 | $30.17 | +72.4% | Buy | — | 39 |
 INSPInspire Medical Systems, Inc. | $2.1B | $71.30 | $60.80 | -14.7% | Hold | 59.7x | 27 |
 EWEdwards Lifesciences Corporation | $51.1B | $88.78 | $101.70 | +14.6% | Buy | 29.6x | 49 |
 ALGNAlign Technology, Inc. | $11.0B | $153.29 | $205.25 | +33.9% | Buy | 13.6x | 33 |
 HOLXHologic, Inc. | $17.0B | $76.01 | $78.69 | +3.5% | Hold | 17.2x | 42 |
 IRTCiRhythm Technologies, Inc. | $3.6B | $110.53 | $174.88 | +58.2% | Buy | — | 20 |
 RXSTRxSight, Inc. | $204M | $4.93 | $7.50 | +52.1% | Hold | — | 12 |
 LNTHLantheus Holdings, Inc. | $6.5B | $100.00 | $104.48 | +4.5% | Buy | 18.5x | 19 |
Quick answers to the most common questions about buying GKOS stock.
Glaukos Corporation (GKOS) has a consensus 12-month price target of $190.75, implying 19.3% upside from $159.86. The 25 analysts covering GKOS see moderate appreciation potential.
GKOS has a consensus rating of "Buy" based on 25 Wall Street analysts. The rating breakdown is predominantly bullish, with 18 Buy/Strong Buy ratings. The consensus 12-month price target of $190.75 implies 19.3% upside from current levels.
GKOS's current price is $159.86 with a consensus target of $190.75 (19.3% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $215 for GKOS, while the most conservative target is $150. The consensus of $190.75 represents the median expectation. These targets typically reflect 12-month expectations.
GKOS is heavily covered by Wall Street, with 25 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 18 have Buy ratings, 6 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month GKOS stock forecast based on 25 Wall Street analysts shows a consensus price target of $190.75, with estimates ranging from $150 (bear case) to $215 (bull case). The median consensus rating is "Buy".
Wall Street analysts are optimistic on GKOS, with a "Buy" consensus rating and $190.75 price target (19.3% upside). 18 of 25 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
GKOS analyst price targets range from $150 to $215, a 34% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $190.75 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.